
|Videos|November 27, 2017
How the Treatment Paradigm for EGFR+ Lung Cancer Will Transform
Author(s)Justin F. Gainor, MD
Justin F. Gainor, MD, medical oncologist, Assistant Professor of Medicine, Massachusetts General Hospital, Harvard Medical School, discusses how the treatment paradigm for EGFR+ lung cancer will transform over the next several years.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves T-DXd Plus Pertuzumab for HER2-Positive Breast Cancer
2
Teclistamab/Daratumumab Earns FDA Priority Voucher for R/R Myeloma
3
Roxadustat Granted Orphan Drug Designation for Myelodysplastic Syndromes
4
FDA Fast-Tracks Muzastotug Combo in MSS Metastatic Colorectal Cancer
5










































